Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study by Pierga, Jean-Yves, Prof, Petit, Thierry, Prof, Delozier, Thierry, MD, Ferrero, Jean-Marc, Prof, Campone, Mario, MD, Gligorov, Joseph, MD, Lerebours, Florence, MD, Roché, Henri, Prof, Bachelot, Thomas, MD, Charafe-Jauffret, Emmanuelle, Prof, Pavlyuk, Maria, MD, Kraemer, Sandrine, MSc, Bidard, François-Clément, MD, Viens, Patrice, Prof

Get full text